Otsuka Pharmaceutical
在场
是其中之一......
Otsuka Holdings 是一家在股票代码 4578 (JP) 下上市的公司。
Otsuka Holdings 在 10 个国家有直接业务。Otsuka Holdings 拥有 25家子公司，其中包括 Astex、Astex Pharmaceuticals 和 Cambridge Isotope Laboratories。
他们在：
涉及Otsuka Holdings的并购和融资。
- Otsuka Pharmaceutical has announced the acquisition of Jnana Therapeutics (公布2024八月1号).
高管
查看带有其 164 名主要高管的组织结构图
Otsuka Pharmaceutical 搜索最多的简介
- Makoto Inoue, President and Representative Director
- Hiroshi Sugawara, Board Member
- Susumu Tamai, Vice Chairman of the Board
创建提醒
跟踪 Otsuka Pharmaceutical 的高管变动
药店
Otsuka Holdings 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Otsuka Pharmaceutical 的最新新闻稿
- Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company’s Carbon Neutrality Initiative | Otsuka Group News | Otsuka Holdings Co., Ltd.searchsearchBack ButtonSearch IconFilter Icon
- Heartful Kawauchi ReceivedJapan Organization for Employment of the Elderly, Persons with Disabilities and Job Seekers President's Award｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -｜News Releases | Otsuka Pharmaceutical C
- Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Advancing Women's Health Business Bonafide Health Launched "Thermella", a Plant-derived Supplement to Support Menopausal Women in the U.S.｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical signs global supporter agreement with World AthleticsSponsorship will cover the World Athletics Championships Tokyo 25POCARI SWEAT will support the event with the key message "Believe In Your Potential."｜News Releases | Otsuka Pharma
- Otsuka Pharmaceutical Launches Corporate Health Support Program "fitbiz"Supporting Employees in Building and Maintaining Healthy Habits｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- View more press releases Close
通过电子邮件
